Before 2016: Cigars Largely Unregulated at the Federal Level

The Family Smoking Prevention and Tobacco Control Act of 2009 gave the FDA authority to regulate tobacco products — but the act explicitly applied to cigarettes, roll-your-own tobacco, and smokeless tobacco. Cigars were not included in the initial grant of authority. Through 2016, premium cigars were regulated primarily at the state level through age-of-sale laws and at the point of import through US Customs for trade compliance. Federal excise tax applied, but the FDA's product standards, labeling requirements, and premarket authorization framework did not.

The 2016 Deeming Rule

In May 2016, the FDA published its final deeming rule, extending regulatory authority under the Tobacco Control Act to all tobacco products not already covered — including, for the first time, premium cigars, pipe tobacco, hookah tobacco, and e-cigarettes. The deeming rule became effective August 8, 2016.

The deeming rule made cigars "deemed tobacco products" subject to the full Tobacco Control Act framework. In theory, this meant cigars were subject to every requirement the act imposed — including the premarket review requirement that would have required manufacturers to obtain FDA approval for every cigar product introduced after February 15, 2007.

The Predicate Date Problem
The Tobacco Control Act requires that new tobacco products receive FDA authorization before sale. Products sold on February 15, 2007 are grandfathered as predicate products. For the cigar industry, this meant every cigar introduced after that date — the vast majority of products in the 2016 market — would theoretically require a Substantial Equivalence report or premarket tobacco authorization costing hundreds of thousands to millions of dollars per product line.

What the Rules Currently Require

In practice, the FDA has repeatedly extended compliance deadlines and narrowed its enforcement approach for premium handmade cigars specifically. The operational requirements as of the mid-2020s include:

Required Health Warnings

All cigar packaging and advertising must carry one of the following FDA-required warning statements, rotated across marketing materials:

  • WARNING: This product contains nicotine. Nicotine is an addictive chemical.
  • WARNING: Cigar smoking can cause cancers of the mouth and throat, even if you do not inhale.
  • WARNING: Cigar smoking can cause lung cancer and heart disease.
  • WARNING: Cigars are not a safe alternative to cigarettes.
  • WARNING: Tobacco smoke increases the risk of lung cancer and heart disease, even in nonsmokers.

Warning labels must meet specific size, placement, and contrast requirements. For packaging, the warning must appear on both the principal display panel and the information panel.

Registration and Listing

Cigar manufacturers, importers, and retailers that mix or repack cigars are required to register with the FDA and submit product listings. Retailers that sell cigars only in their original, sealed packaging are generally not required to register.

Age Verification and Free Samples

The federal minimum purchase age is 21 under the Tobacco 21 law signed in December 2019. Retailers must verify age for all tobacco purchases. Online cigar retailers must verify age at checkout and use adult-signature-required shipping. Free samples of cigars are prohibited — a significant change from prior practice, as sample distribution had been a primary marketing channel for boutique brands at trade events and retail.

The Premarket Authorization Question

The most significant ongoing issue — and the one that could structurally reshape the entire premium cigar market — is whether the FDA will enforce premarket authorization requirements for cigars introduced after 2007. If enforced strictly, most products on the market would require either a Substantial Equivalence demonstration or a new product authorization, a process costing hundreds of thousands to millions of dollars per product line.

The FDA has repeatedly deferred enforcement for premium cigars specifically, acknowledging the enormous administrative burden the premarket review system would impose. Legislative efforts to formally exempt premium handmade cigars from premarket review have been introduced in Congress multiple times. None has become law. The regulatory limbo continues — technical applicability of the full framework with enforcement repeatedly deferred for key provisions.

The Premium Cigar Exemption Debate

The core industry argument is that premium handmade cigars are fundamentally different from cigarettes: they are typically not inhaled, consumed far less frequently, and the consumer profile is adult and deliberate rather than dependent and habitual. The public health community generally opposes blanket exemptions, noting that premium cigars still deliver nicotine and produce carcinogenic combustion byproducts regardless of inhalation pattern.

State and Local Regulations

Beyond federal requirements, the cigar industry operates within a patchwork of state and local rules:

  • State excise taxes: Vary enormously — some states tax cigars at a percentage of wholesale price (ranging from 10 percent to over 100 percent); others use per-cigar flat rates. These taxes directly affect retail pricing and influence where customers choose to purchase online.
  • Smoking ban exemptions: Many state and municipal indoor smoking bans include exemptions for tobacco retail establishments, cigar bars, and cigar lounges. The extent of these exemptions varies — some require the venue derive a minimum percentage of revenue from tobacco sales; others are absolute with no exemptions.
  • Online sales restrictions: Some states restrict or prohibit interstate mail-order tobacco sales to residents. Online retailers must navigate this patchwork in addition to the federal framework.

What This Means for Retailers and Consumers

For retailers, the practical requirements are age verification, compliant warning labeling on all marketing materials, applicable FDA registration, and adult-signature shipping for online orders. The most significant ongoing risk is the premarket authorization question — if the FDA changes its enforcement posture, the product landscape could shift substantially.

For consumers, the most visible impact is the warning labels now present on all cigar packaging. The broader market-structure implications — if premarket authorization were strictly enforced, many boutique brands would be financially unable to comply — affect long-term availability and variety in the premium segment.